Budesonide sustained release capsule - Jiangsu Hengrui Medicine
Latest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III IgA nephropathy
- Phase II Autoimmune hepatitis
Most Recent Events
- 22 Oct 2024 Phase-II clinical trials in Autoimmune hepatitis (Monotherapy) (PO) (Jiangsu Hengrui Medicine pipeline, October 2024)
- 22 Oct 2024 Phase-III clinical trials in IgA nephropathy (Monotherapy) (PO) (Jiangsu Hengrui Medicine pipeline, October 2024)